Can Fite BioPharma Ltd (CANF)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027

Interim analysis to be conducted under an FDA- and EMA-agreed protocol Ramat Gan, Israel, July 06, 2026...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease;...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology

The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson

Ramat-Gan, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026

Company to Conduct Partnering Meetings Focused on Oncology, Liver Disease and Inflammatory Disease RAMAT GAN...

Form 4 - Statement of changes in beneficial ownership of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism

Growing momentum for RAS inhibition at ASCO highlights Namodenoson’s RAS pathway inhibition and encouraging...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]